Team:UC Davis/Criteria
From 2012.igem.org
Line 1,213: | Line 1,213: | ||
<li><b>Outline and detail a new approach to an issue of Human Practice in synthetic biology as it relates to your project, such as safety, security, ethics, or ownership, sharing, and innovation.</b></li> | <li><b>Outline and detail a new approach to an issue of Human Practice in synthetic biology as it relates to your project, such as safety, security, ethics, or ownership, sharing, and innovation.</b></li> | ||
We developed a <a href="https://static.igem.org/mediawiki/2012/3/37/UCDavis_IGEMWorksheet.pdf">lesson plan</a> for middle school students that furthers the sharing portion of the human practices requirement. We believe that as undergraduates, actually conducting the protocols through a hands-on approach is significantly more beneficial opposed to reading text out of a textbook, and furthermore, that exposure to the field of synthetic biology early on can be extremely beneficial to students in foundationalizing their understanding of many topics that will not even be introduced until the collegiate tier of higher education. | We developed a <a href="https://static.igem.org/mediawiki/2012/3/37/UCDavis_IGEMWorksheet.pdf">lesson plan</a> for middle school students that furthers the sharing portion of the human practices requirement. We believe that as undergraduates, actually conducting the protocols through a hands-on approach is significantly more beneficial opposed to reading text out of a textbook, and furthermore, that exposure to the field of synthetic biology early on can be extremely beneficial to students in foundationalizing their understanding of many topics that will not even be introduced until the collegiate tier of higher education. | ||
- | <br> | + | <br><br> |
We also developed an economic toolkit that addresses the ownership, sharing, and innovation aspect of the human practices requirement. By conducting an in-depth analysis of the intellectual property, legal issues that arise, and their relation to the iGEM competition, teams reading our deliverable will hopefully gain a cohesive understanding of the importance of protecting innovation. <br> | We also developed an economic toolkit that addresses the ownership, sharing, and innovation aspect of the human practices requirement. By conducting an in-depth analysis of the intellectual property, legal issues that arise, and their relation to the iGEM competition, teams reading our deliverable will hopefully gain a cohesive understanding of the importance of protecting innovation. <br> | ||
A full description of our human practice advances can be found on our <a href="https://2012.igem.org/Team:UC_Davis/Human_Practices">Human Practices</a> page.<br> | A full description of our human practice advances can be found on our <a href="https://2012.igem.org/Team:UC_Davis/Human_Practices">Human Practices</a> page.<br> |
Revision as of 23:36, 3 October 2012
Comments for the Judges
Judging Criteria
Silver Gold
Our team was registered at the start of summer, everyone had a wonderful time working on the project, and we are eager to present at Stanford in October!
This form has been completed and we have added this page to our wiki to further elaborate.
We have created this wiki, which describes our work, parts and results. For more information concerning our project please view our Project page. Additionally we have detailed 19 new parts, as well as sent in DNA of 7 of those parts into the Registry of Standard Biological Parts along with their appropriate sequences and data.
We plan to present both a poster and a talk at the regional Jamboree in Stanford on Oct. 12-14, 2012.
We have entered information detailing 19 new BioBrick parts, both with DNA sequences and data into the Registry. For more information about these parts please view our Parts page
We have submitted DNA for 7 new parts to the Registry, specifically Bba_K936000, Bba_K936013, Bba_K936016, Bba_K936017, Bba_K936020, Bba_K936021, and Bba_K936024. We also submitted our ethylene-glycol degrading strain E-15 EG3, Bba_K936035 to the registry in the form of a glycerol stock. We chose to only send the samples that we had absolute confidence in and we plan to have the remaining planned parts along with our LC Cutinase mutants sent to the Registry as soon as possible.
We also developed an economic toolkit that addresses the ownership, sharing, and innovation aspect of the human practices requirement. By conducting an in-depth analysis of the intellectual property, legal issues that arise, and their relation to the iGEM competition, teams reading our deliverable will hopefully gain a cohesive understanding of the importance of protecting innovation.
A full description of our human practice advances can be found on our Human Practices page.